-
Bilex Pharma Awarded £15 Million Grant from CEPI to Accelerate Development of Pandemic Preparedness Platform
Bilex Pharma is honoured to announce it has been awarded a significant grant of £15 million from the Coalition for Epidemic Preparedness Innovations (CEPI). This crucial funding will accelerate the development and validation of Bilex Pharma’s rapid-response vaccine platform, a key component of its Project RESPOND pandemic preparedness initiative. Strengthening Global Defences Against Future Pandemics CEPI is…
-
BLX-CHIK01 Chikungunya Vaccine Enters Clinical Trials Following Successful Preclinical Studies
Bilex Pharma is pleased to announce the initiation of Phase 1 clinical trials for BLX-CHIK01, our virus-like particle (VLP) vaccine candidate for chikungunya virus. This important milestone follows the successful completion of comprehensive preclinical studies demonstrating the vaccine’s strong immunogenicity and favorable safety profile. Addressing a Growing Global Health Threat Chikungunya virus is a mosquito-transmitted…
-
Bilex Pharma’s Nipah Virus Vaccine Shows 100% Protection in Preclinical Challenge Studies
Bilex Pharma is pleased to announce that BLX-NIPAH01, our investigational mRNA vaccine candidate against Nipah virus, has demonstrated complete protection in preclinical challenge studies. This significant milestone advances our efforts to develop a vaccine against this deadly emerging pathogen with pandemic potential. Addressing a Serious Emerging Threat Nipah virus is a zoonotic pathogen that causes…
-
Bilex Pharma Launches Project SHIELD to Address Major Respiratory Viral Threats
Bilex Pharma is pleased to announce the launch of Project SHIELD, a comprehensive initiative focused on developing next-generation vaccines against major respiratory viral pathogens. This strategic program integrates the company’s most advanced clinical candidates with innovative research efforts aimed at transforming the prevention of respiratory viral diseases. A Unified Approach to Respiratory Viral Threats Project…
-
BLX-TB01 Tuberculosis Vaccine Candidate Advances to Phase 1 Clinical Trials
Bilex Pharma is pleased to announce that BLX-TB01, our novel tuberculosis (TB) vaccine candidate, has received regulatory approval to begin Phase 1 clinical trials. This milestone marks a significant advancement in the company’s efforts to develop an effective vaccine against one of the world’s deadliest infectious diseases. Addressing a Persistent Global Health Challenge Tuberculosis remains…
-
Bilex Pharma’s mRNA Technology Featured in Nature Biotechnology Publication
Bilex Pharma is proud to announce that our innovative mRNA technology platform has been featured in a peer-reviewed article published in the prestigious journal Nature Biotechnology. The publication highlights the company’s proprietary BiLipid™ delivery system and SAMplify™ self-amplifying mRNA platform, showcasing advances that could significantly enhance mRNA vaccine performance. Groundbreaking Research Recognized in Leading Scientific…
-
New Glasgow Technical Operations Centre Opens, Expanding Bilex Pharma’s UK Footprint
Bilex Pharma is pleased to announce the official opening of its new Technical Operations Centre in Glasgow, Scotland, marking a significant expansion of the company’s UK-based capabilities and strengthening its commitment to building integrated vaccine development and manufacturing expertise within the United Kingdom. Strategic Investment in Scottish Innovation The 5,200 square meter facility, located at…
-
Bilex Pharma Joins Global AMR Vaccine Consortium to Combat Antimicrobial Resistance
Bilex Pharma is proud to announce its membership in the newly formed Global Antimicrobial Resistance (AMR) Vaccine Consortium, a groundbreaking international initiative dedicated to developing innovative vaccines against drug-resistant pathogens. This strategic collaboration brings together leading academic institutions, pharmaceutical companies, and global health organizations in a coordinated effort to address one of the most pressing…
-
RSV Vaccine Candidate Shows Strong Immune Response in Phase 2 Clinical Trial
Bilex Pharma is pleased to announce positive Phase 2 clinical trial results for BLX-RSV01, our investigational vaccine candidate for Respiratory Syncytial Virus (RSV). The trial demonstrated robust immune responses in adults aged 60 and older, a population particularly vulnerable to severe RSV disease. Trial Results Exceed Expectations The randomized, placebo-controlled Phase 2 study enrolled 350…
-
Bilex Pharma Secures £50 Million Series B Funding to Advance Vaccine Pipeline
Bilex Pharma is pleased to announce the successful completion of a £50 million Series B funding round to accelerate the development of its innovative vaccine pipeline and expand its UK operational capabilities. Strategic Investment to Fuel Growth The funding round was led by Oxford Science Enterprises, with significant participation from Cambridge Innovation Capital, SR One,…
About
At Bilex Pharma, we envision a world where innovative vaccines provide effective protection against both established and emerging infectious diseases, enabling healthier communities and more resilient global health systems.
We focus our expertise on significant health challenges where current solutions are inadequate or nonexistent. By targeting diseases with substantial global burden and limited preventive options, we strive to make meaningful contributions to public health where they’re needed most.
Archive
Categories
Recent Posts
- Bilex Pharma Completes Patient Enrollment for Landmark Phase 3 Trial of RSV Vaccine Candidate BLX-RSV01 in Older Adults
- Bilex Pharma’s Next-Generation COVID-19 Vaccine BLX-COVID19 Shows Superior Immune Response with Reduced Dosing in Phase 2 Trial
- Bilex Pharma Awarded £15 Million Grant from CEPI to Accelerate Development of Pandemic Preparedness Platform
- Bilex Pharma’s Universal Influenza Vaccine Candidate Shows Promising Cross-Strain Protection in Phase 2b Interim Analysis
- Bilex Pharma’s Dengue Vaccine Candidate BLX-DEN01 Demonstrates Balanced Immune Response Against All Four Serotypes in Phase 1 Trial